Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.59 |
| ▸ | EP300 | Q09472 | 2/20 | 0.58 |
| ▸ | BRD2 | P25440 | 1/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.53 |
| ▸ | TSPO | P30536 | 1/20 | 0.53 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.53 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16868381 | 0.87 | BRD4 (0.58) | BRD4EP300BRD2ADORA2BTSPO | |
| SCHEMBL16333294 | 0.86 | BRD4 (0.57) | BRD4EP300BRD2ADORA2BTSPO | |
| SCHEMBL20159992 | 0.86 | BRD4 (0.57) | BRD4EP300BRD2ADORA2BTSPO | |
| SCHEMBL6730613 | 0.84 | BRD4 (0.54) | BRD4EP300BRD2ADORA2BTSPO | |
| SCHEMBL16658392 | 0.84 | BRD4 (0.55) | BRD4EP300BRD2ADORA2BTSPO | |
| SCHEMBL16651491 | 0.84 | BRD4 (0.55) | BRD4EP300BRD2ADORA2BTSPO | |
| SCHEMBL15558963 | 0.82 | BRD4 (0.61) | BRD4EP300BRD2ADORA2BTSPO | |
| SCHEMBL29548942 | 0.81 | BRD4 (0.65) | BRD4EP300BRD2ADORA2BTSPO | |
| SCHEMBL28720367 | 0.81 | BRD4 (0.65) | BRD4EP300BRD2ADORA2BTSPO | |
| SCHEMBL29548742 | 0.80 | BRD4 (0.58) | BRD4EP300BRD2ADORA2BTSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4134364-A2 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| EP-3741758-A1 | BROMODOMAIN INHIBITOR COMPOUND AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2020-11-25 | — | — | EP | disclosed |
| EP-3640241-A1 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2020-04-22 | — | — | EP | disclosed |
| EP-3290407-A1 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc (US) | 2018-03-07 | — | — | EP | disclosed |
| US-20170158709-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-06-08 | — | — | US | disclosed |
| US-9598372-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160115134-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-28 | — | — | US | disclosed |
| US-9115114-B2 | Bromodomain inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9034900-B2 | Bromodomain inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-05-19 | — | — | US | disclosed |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158709-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD4 5/4885EP300 2/4885BRD2 8/4885 |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD4 5/4885EP300 2/4885BRD2 8/4885 |
| US-20160115134-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD4 5/4885EP300 2/4885BRD2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.